Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Banks Bourne, Founder & Chief Executive Officer at Bourne Partners. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Banks, covering: How making a bet in the right place at the right time sparked an extraordinary journey in pharma investing. The founding of Bourne Partners and a twenty five plus year ride through multiple market cycles. Lessons from hundreds of deals, and why the best investments are often the most complex and hardest won. Why running from ego and listening obsessively to clients is one of the most underrated advantages in private equity. Why private equity has become increasingly commoditised, and why Banks believes momentum is building and sentiment is turning positive heading into 2026. As Founder and CEO, Banks oversees all business operations and direct investment opportunities at Bourne Partners. He and the firm have been party to more than $10 billion of transactions in the pharmaceutical (“pharma”), pharma services, and consumer healthcare sectors. Banks is also the founder of Tanner Pharma Group, a pharma services company dedicated to providing managed access, commercialization, and clinical trials services to patients and partners in more than 100 countries. For almost 20 years, Bourne Partners has transacted with nearly all major pharmaceutical and specialty pharmaceuticals companies around the world, including Banks’ initial investment in King Pharmaceuticals in the late 1990’s. This investment introduced Banks to the pharmaceutical world and jump started his interest in the healthcare sector. Since then, he has invested in more than 200 private companies / assets. While Banks has derived great satisfaction by offering focused advisory services to, and investing in, pharma, healthcare, and consumer-oriented companies that need strategic and operational insights, he is even more gratified knowing that his work has helped companies to improve the health and well-being of patients across the world. Banks is passionate about providing healthcare, and specifically pharmaceuticals, to less fortunate patients, as demonstrated by supporting The Max Foundation, Partners in Health, The Bourne Foundation, The Levine Children’s Hospital, and other non-profit organizations. He received a B.A. degree in Business Management (Magna Cum Laude) from North Carolina State University and an M.B.A. from Wake Forest University. He is a member of Young Presidents Organization (YPO). Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO and C-suite leaders from the CDMO ecosystem, exploring two simple questions that reveal what’s really happening inside the building: What’s the biggest internal business challenge for the year ahead?And what’s the biggest opportunity inside their business in 2026? Your host, Raman Sehgal, brings together a punchy set of operator insights spanning commercial readiness, capacity decisions, flawless execution, commercial excellence, and the shift toward deeper partnerships and integrated models. Show features insights from: Ankit Gupta, CEO, InstaPill Nick Fortin, CEO, Codis Eric Edwards, MD, PhD, CEO, Phlow USA Jason Anderson, CEO, ensera Dirk T. Lange, CEO, Pyramid Pharma Services Philip Macnabb, CEO, Curia Matthew Bio, CSO, Cambrex and President, Snapdragon Chemistry Bruce Thompson, CTO, Kincell Bio Bill Vincent, Biotech Entrepreneur, CEO and Board Member Derek Hennecke, Founder, Investor and Board Member Stephen Dilly, CEO, Sonoma Biotherapeutics Elisabeth Stampa, CEO, Medichem Christiane Bardroff, COO Leader Kaan-Fabian Kekec, Partner, Simon-Kucher Healthcare and Life Sciences Ian Tzeng, Managing Director, L.E.K. Consulting Adam Siebert, Managing Director, L.E.K. Consulting J.D. Mowery, President, CDMO Division, Bora Pharmaceuticals Jon Alberdi, CEO, Vivebiotech Peter Belden, President, US, Tjoapack Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO/c-suite leaders from the CDMO space, who discuss the big headwinds for the pharmaceutical and biotechnology space for 2026. Show features: Christiane Bardroff, Chief Operating Officer (COO) at Rentschler Biopharma SE Philip Macnabb, Chief Executive Officer at Curia Kaan-Fabian Kekec, Partner at Simon-Kucher‘s Healthcare & Life Sciences division Dirk T. Lange , Chief Executive Officer at Pyramid Pharma Services Bruce Thompson, CTO at Kincell Bio Bill Vincent, Biotech Entrepreneur, CEO, Board Member Derek Hennecke - founder, investor, board member Matthew Bio, CSO at Cambrex & President, Snapdragon Chemistry Stephen Dilly, CEO at Sonoma Biotherapeutics, Stephen Dilly, CEO at Sonoma Biotherapeutics, Bill Humphries, Chief Executive Officer at Medpharm Elisabeth Stampa, CEO at Medichem Kerstin Dolph, SVP of Manufacturing at Charles River Labs Eric Edwards, Chief Executive Officer at Phlow-USA Peter DeYoung, CEO at Piramal Pharma Ian Tzeng, Managing Director at L.E.K. Consulting Adam Siebert, Managing Director at L.E.K. Consulting J.D. Mowery, President CDMO Division Bora Pharmaceuticals Peter Belden President, US, Tjoapack Nick Fortin, CEO CODIS Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO/c-suite leaders from the CDMO space, who discuss the optimism levels for the pharmaceutical and biotechnology space for 2026. Guests include: Christiane Bardroff, Chief Operating Officer (COO) at Rentschler Biopharma SE Philip Macnabb, Chief Executive Officer at Curia Kaan-Fabian Kekec, Partner at Simon-Kucher‘s Healthcare & Life Sciences division Dirk T. Lange , Chief Executive Officer at Pyramid Pharma Services Bruce Thompson, CTO at Kincell Bio Bill Vincent, Biotech Entrepreneur, CEO, Board Member Derek Hennecke - founder, investor, board member Matthew Bio, CSO at Cambrex & President, Snapdragon Chemistry Stephen Dilly, CEO at Sonoma Biotherapeutics, Bill Humphries, Chief Executive Officer at Medpharm Elisabeth Stampa, CEO at Medichem Philip Lee, CEO at GeneFab Kerstin Dolph, SVP of Manufacturing at Charles River Labs Eric Edwards, Chief Executive Officer at Phlow-USA Peter DeYoung, CEO at Piramal Pharma Ian Tzeng, Managing Director at L.E.K. Consulting Adam Siebert, Managing Director at L.E.K. Consulting J.D. Mowery, President CDMO Division Bora Pharmaceuticals Peter Belden President, US, Tjoapack Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Gale, Founding Partner & Managing Director at Signet. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering: The origins of growth equity in private equity and how it led to the founding of Signet, a fund built on deep domain expertise. Why private equity is a growing asset category but still remains undervalued and under appreciated. How the nature of the companies Signet invests in has evolved over the last twenty five years, while the fundamental principles of building a strong business remain the same. How the “picks and shovels” strategy of investing in tools, services and infrastructure has consistently served them well. Jim’s assessment criteria when evaluating new opportunities after seventy deals, including the key question… can we institutionalise an entrepreneur led business. How higher interest rates and economic uncertainty constrain biopharma and biotech, and how that impacts investment dollars flowing into pharma services, along with deal flow, valuation and structure. James “Jim” Gale is the Founding Partner and Managing Director of Signet Healthcare Partners, a New York based healthcare growth equity firm specialising in pharmaceutical services, specialty pharma and medical technology. With more than thirty five years of investing and finance experience, Jim has built a deep track record backing companies involved in formulation, development, manufacturing and commercialisation across the world. At Signet, Jim has led investments across the pharma services value chain, including platforms in sterile fill finish, complex formulations, biologics development and specialty generics. His current and recent board roles include Ascendia Pharmaceutical Solutions, NorthX Biologics, RK Pharma, Bionpharma, Chr Olesen Synthesis, Pharma Nobis, Juno Pharmaceuticals and Lee’s Pharmaceutical. He also serves as Chairman of Bionpharma and is a director of Knight Therapeutics. Jim holds an MBA from the University of Chicago Booth School of Business. Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Thomas Dobmeyer, medical, entrepreneur and investor at ekwithree. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering: Choosing to freelance and consult as a medic after qualifying in medicine. Co-founding a niche regulatory affairs firm and growing it into a 3,000-person multinational pharmaceutical solutions organisation. Expanding into new countries, acquisitions, and domains to build scale and credibility in biopharma — with culture as the secret weapon. Why lawmakers and regulators became his best salespeople, and how increasing complexity, internationalisation, and market growth ultimately led to a $1.4B exit to Cencora. Life after the sale as an active investor and mentor — and the key trends Thomas sees shaping the future of drug development. Dr. Thomas Dobmeyer is a physician, researcher, and entrepreneur currently serving as a partner at ekwithree GmbH, a growth investment firm specializing in technology-driven B2B service providers. In this role, Thomas plays a key part in driving the organizational success of ekwithree and its diverse portfolio of companies. With over two decades of extensive experience in the pharmaceutical and medical technology industries, Thomas was founder and CEO of PharmaLex GmbH. There, he spearheaded the transformation of a startup consulting boutique into a globally recognized unicorn company operating in 40 countries with 3,500 employees. His strategic expertise was instrumental in shaping and executing the company’s business strategies, overseeing leadership team formation, advising on strategic matters, and ensuring the implementation of robust business plans to achieve corporate objectives. Under his leadership, PharmaLex successfully completed nearly 40 mergers and acquisitions, significantly expanding its global business model and footprint. Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!